Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 165

1.

Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.

Takahara N, Nakai Y, Isayama H, Sasaki T, Satoh Y, Takai D, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tada M, Yatomi Y, Koike K.

Cancer Chemother Pharmacol. 2013 Jan;71(1):85-92. doi: 10.1007/s00280-012-1981-0. Epub 2012 Sep 29.

PMID:
23053265
[PubMed - indexed for MEDLINE]
2.

Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.

Park SR, Kong SY, Rhee J, Park YI, Ryu KW, Lee JH, Kim YW, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim NK.

Ann Oncol. 2011 Apr;22(4):890-6. doi: 10.1093/annonc/mdq435. Epub 2010 Sep 22.

PMID:
20860988
[PubMed - indexed for MEDLINE]
Free Article
3.

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).

Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y.

Gastric Cancer. 2011 Mar;14(1):72-80. doi: 10.1007/s10120-011-0009-5. Epub 2011 Feb 23.

PMID:
21340666
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.

Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, Nakachi K, Najima M, Ogura T, Suzuki E.

Cancer Chemother Pharmacol. 2009 Jan;63(2):313-9. doi: 10.1007/s00280-008-0741-7. Epub 2008 Apr 9.

PMID:
18398614
[PubMed - indexed for MEDLINE]
5.

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer.

Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2009 May;63(6):1141-5. doi: 10.1007/s00280-008-0839-y. Epub 2008 Oct 7.

PMID:
18839175
[PubMed - indexed for MEDLINE]
7.

Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.

Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda M, Fukuda M, Takatani H, Nagashima S, Soejima Y, Kasai T, Nakatomi K, Masuda N, Tsukamoto K, Kohno S.

J Thorac Oncol. 2011 Jan;6(1):121-7. doi: 10.1097/JTO.0b013e318200e4e8.

PMID:
21150467
[PubMed - indexed for MEDLINE]
8.

UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.

Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY, Xu JM.

World J Gastroenterol. 2012 Dec 7;18(45):6635-44. doi: 10.3748/wjg.v18.i45.6635.

PMID:
23236239
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.

Oh SY, Kim HJ, Kim TH, Lee GW, Kim HG, Jeong CY, Kwon HC, Kang JH.

Invest New Drugs. 2010 Jun;28(3):343-9. doi: 10.1007/s10637-009-9265-1. Epub 2009 May 15.

PMID:
19444385
[PubMed - indexed for MEDLINE]
10.

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M.

Br J Cancer. 2004 Aug 16;91(4):678-82.

PMID:
15280927
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702).

Mochizuki Y, Ohashi N, Kojima H, Ishigure K, Kinoshita T, Eguchi T, Fujitake S, Ito S, Fujiwara M, Kodera Y.

Cancer Chemother Pharmacol. 2013 Sep;72(3):629-35. doi: 10.1007/s00280-013-2235-5. Epub 2013 Jul 24.

PMID:
23881212
[PubMed - indexed for MEDLINE]
12.

Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.

Okuyama Y, Hazama S, Nozawa H, Kobayashi M, Takahashi K, Fujikawa K, Kato T, Nagata N, Kimura H, Oba K, Sakamoto J, Mishima H.

Jpn J Clin Oncol. 2011 Apr;41(4):477-82. doi: 10.1093/jjco/hyr001. Epub 2011 Feb 7.

PMID:
21303789
[PubMed - indexed for MEDLINE]
Free Article
13.

Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.

Poon D, Chowbay B, Cheung YB, Leong SS, Tan EH.

Cancer. 2005 Feb 1;103(3):576-81.

PMID:
15612023
[PubMed - indexed for MEDLINE]
Free Article
14.

Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.

Sudo K, Yamaguchi T, Nakamura K, Denda T, Hara T, Ishihara T, Yokosuka O.

Cancer Chemother Pharmacol. 2011 Feb;67(2):249-54. doi: 10.1007/s00280-010-1311-3. Epub 2010 Mar 30.

PMID:
20352216
[PubMed - indexed for MEDLINE]
15.

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.

Font A, Sánchez JM, Tarón M, Martinez-Balibrea E, Sánchez JJ, Manzano JL, Margelí M, Richardet M, Barnadas A, Abad A, Rosell R.

Invest New Drugs. 2003 Nov;21(4):435-43.

PMID:
14586211
[PubMed - indexed for MEDLINE]
16.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

PMID:
11743211
[PubMed - indexed for MEDLINE]
Free Article
17.

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.

Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V.

Br J Cancer. 2006 Sep 4;95(5):587-92. Epub 2006 Aug 8.

PMID:
16909140
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer.

Sasaki T, Isayama H, Nakai Y, Takahara N, Satoh Y, Takai D, Kogure H, Yamamoto N, Hirano K, Tada M, Yatomi Y, Koike K.

Anticancer Res. 2013 Jun;33(6):2619-22.

PMID:
23749917
[PubMed - indexed for MEDLINE]
19.

UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ.

World J Gastroenterol. 2009 Oct 28;15(40):5058-66.

PMID:
19859999
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy.

Lee DJ, Lee J, Lee HY, Lim T, Lee SJ, Yi SY, Park SH, Park JO, Lim HY, Kang WK, Park YS.

Med Oncol. 2011 Dec;28 Suppl 1:S291-4. doi: 10.1007/s12032-010-9755-1. Epub 2010 Nov 30.

PMID:
21116875
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk